Faculty of Health Sciences

Delaying treatment for localised prostate cancer does not increase mortality risk, trial shows

Active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery, reports the largest study of its kind today. The latest findings from the ProtecT trial, led by the Universities of Bristol and Oxford, are presented today [12 March] at the European Association of Urology (EAU) Congress in Milan and published in the New England Journal of Medicine.